OBJECTIVE: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. METHODS: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. RESULTS: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA 1c ), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoproteincholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA 1c , LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE. CONCLUSIONS: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
Introduction
Microalbuminuria in type 2 diabetes is not only a marker for diabetic nephropathy, but is also a predictor for future cardiovascular events. 1 Hypercholesterolaemia, a wellknown risk factor for cardiovascular disease (CVD), has been reported to contribute to the progression of chronic kidney disease T Nakamura, E Sato, M Amaha et al. Effects of ezetimibe on urinary albumin in diabetic microalbuminuria (CKD) . 2, 3 Since statins have been shown to offer significant reductions in cardiovascular and/or renal morbidity in type 2 diabetes with albuminuria, 2,3 control of hypercholesterolaemia may be an appropriate therapeutic target for preventing the onset of CVD and slowing the progression of CKD in these patients. There is, however, still controversy as to whether control of hypercholesterolaemia by statins is effective in reducing urinary albumin excretion (UAE) in type 2 diabetes patients with microalbuminuria. 3, 4 Ezetimibe is a lipid-lowering agent that selectively inhibits intestinal cholesterol absorption. 5 To our knowledge, little has been published on the effects of ezetimibe on microalbuminuria in patients with type 2 diabetes. The present study investigated the effect of ezetimibe treatment on UAE in type 2 diabetes patients with microalbuminuria.
Patients and methods

STUDY POPULATION
Consecutive type 2 diabetes patients with hypercholesterolaemia, defined as a lowdensity lipoprotein-cholesterol (LDL-C) serum concentration ≥ 140 mg/dl, and microalbuminuria, defined as a UAE ≥ 30 mg/g creatinine but < 300 mg/g creatinine, from Shinmatsudo Central General Hospital, Chiba, Japan, were enrolled in the study between January and December 2009. Patients with chronic pulmonary disease, collagen disease, liver disease, neoplastic disorders, those who had recent (< 6 months) acute coronary syndrome, stroke or any acute infections, and those with a serum creatinine level > 1.2 mg/dl were excluded from the study.
All patients received 10 mg ezetimibe once daily, with no statins or other antihypercholesterolaemic agents, for 6 months. During the study period, subjects were instructed not to change their lifestyles and to continue taking the same dose of any concomitant drugs.
Written informed consent was obtained from all the study participants. The study protocol was approved by the Ethical Committee of Shinmatsudo Central General Hospital and the study complied with the principles of the Helsinki Declaration.
CLINICAL AND LABORATORY ASSESSMENTS
Patients were assessed at baseline and following 6 months of treatment with ezetimibe. Height and weight were measured, and body mass index (BMI) was calculated. Measurements of systolic and diastolic blood pressure were made in the sitting position using an upright standard sphygmomanometer. Blood was collected into Vacutainer ® tubes (BD, Franklin Lakes, NJ, USA) without ethylenediaminetetraacetic acid or heparin after a 12-h fast. Serum was then separated by centrifugation (3000 rpm, 15 min) and stored at -80°C until use for determination of serum glycated haemoglobin (HbA 1c ), serum creatinine, blood urea nitrogen, serum albumin, serum monocyte chemoattractant protein-1 (MCP-1) and serum lipid profiles, including LDL-C, triglycerides (TG) and HDL-cholesterol (HDL-C. Standard enzymatic methods or enzymelinked immunosorbent assays were used as described previously. 5,6 The LDL-C level was calculated using Friedewald's formula. 7 A 24-h urine sample was collected from each patient and stored at -80°C until use. Urinary albumin excretion was measured using an immunoturbidimetry assay in a Hitachi 7070 automated analyser (Hitachi, Tokyo, Japan). Estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease equation modified for the Japanese population. 8 T Nakamura, E Sato, M Amaha et al.
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STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® statistical software, version 18 (SPSS Inc., Chicago, IL, USA) for Windows ® . The mean ± SD for data were calculated as appropriate. For statistical comparisons of values at baseline and after ezetimibe treatment, a paired, two-tailed dependent ttest was used. Correlations between clinical and laboratory parameters and UAE were calculated using univariate analyses, and independent determinants of UAE were determined using multiple stepwise regression analysis. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 32 type 2 diabetes patients with hypercholesterolaemia and microalbuminuria were enrolled in the study. Their demographic and clinical characteristics are given in Table 1 .
Clinical and laboratory variables at baseline and after 6 months of ezetimibe treatment are shown in Table 2 . Ezetimibe treatment was associated with significant decreases in serum HbA 1c , LDL-C, TG and UAE, and significant increases in serum HDL-C and albumin. The mean concentration of serum MCP-1 decreased after ezetimibe treatment, but the difference between the two groups was not statistically significant.
Univariate analysis showed a significant correlation between UAE and BMI, systolic and diastolic blood pressures, HbA 1c , LDL-C, eGFR (inverse), creatinine and MCP-1 (P < 0.05 for all comparisons; Table 3 ). Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA 1c and MCP-1 were independent determinants of UAE (coefficient of determination R 2 = 0.280).
Discussion
The present study demonstrated that ezetimibe treatment for 6 months significantly reduced UAE in type 2 diabetes patients with hypercholesterolaemia and microalbuminuria. Although ezetimibe treatment only modestly and nonsignificantly decreased serum MCP-1 protein levels, multiple regression analysis showed that serum MCP-1 and serum HbA 1c , but not lipid parameters, were independent determinants of UAE.
The level of circulating MCP-1 has been shown to be significantly higher in type 1 diabetes patients with microalbuminuria and poorer glycaemic control compared with normoalbuminuric patients and healthy controls. 9 Furthermore, type 2 diabetes patients with macroalbuminuria have a significantly higher circulating MCP-1 concentration than those with normo-or microalbuminuria. 10 Given the pathological role of MCP-1 in the early phase of diabetic Data presented as mean ± SD or n of patients. absorption of oxidized cholesterol. This is consistent with a previous report that ezetimibe decreased proteinuria and urinary excretion of 8-hydroxydeoxyguanosine , an oxidative stress marker, in nondiabetic patients with CKD. 5 In addition, it has recently been shown that ezetimibe reduced the oxidized LDL-C level in patients with hypercholesterolaemia. 13 Although the decrease in HbA 1c after ezetimibe treatment was slight and may or may not have been related to ezetimibe therapy, it was statistically significant. Furthermore, HbA 1c was found to be an independent determinant of UAE. Yagi et al. 14 reported that ezetimibe reduced UAE, urinary 8-OHdG and circulating levels of inflammatory biomarkers, such as tumour necrosis factor-α and C-reactive protein, and ameliorated insulin resistance in hypercholesterol aemic patients with microalbumin uria. Thus, ezetimibe may reduce UAE partly by improving insulin sensitivity and glucose metabolism.
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Ezetimibe has also been shown to improve atherogenic lipoprotein profiles, but its effect on albuminuria was modest and not significant in type 2 diabetes patients already receiving simvastatin. 15 The differences in duration of ezetimibe therapy (6 months versus 2 months), degree of albuminuria (UAE of approximately 90 mg/g creatinine versus 5 µg/min creatinine, equivalent to approximately 7 mg/g creatinine), and statin use could explain the discrepancy between the results of Ruggenenti et al. 15 and the present study.
In conclusion, the present study suggests that ezetimibe may ameliorate albuminuria partly via its anti-inflammatory properties in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. Reduction of LDL-C by ezetimibe may be a promising strategy for halting the progression of CKD and CVD in these high-risk subjects.
